Pervasis Therapeutics Successfully Completes Enrollment for Vascugel Trials

Pervasis Therapeutics announced that it has successfully completed patient recruitment for its two Phase II clinical trials involving Vascugel, a treatment for vascular access failure.

According to Pervasis, vascular access failure is a major complication in providing care to patients on hemodialysis to treat end-stage renal disease.

The Phase II clinical studies will evaluate the continued safety of Vascugel, as well as its efficacy in the maintenance of vascular patency after creation of arteriovenous (AV) access grafts and AV fistulae in patients with end-stage renal disease, the company said.

Recent Phase I results for Vascugel demonstrated that all primary endpoints of the study were achieved, with no significant safety issues, the company added.